Copyright ©The Author(s) 2023.
World J Gastroenterol. Aug 14, 2023; 29(30): 4628-4641
Published online Aug 14, 2023. doi: 10.3748/wjg.v29.i30.4628
Table 1 The immunotherapies for resectable esophageal cancer patients
Number of patients
Treatment regimens
CamrelizumabWu et al[48], 202112Cisplatin + paclitaxel + camrelizumab = 8; carboplatin + paclitaxel + camrelizumab = 4MPR, 5/7 (71.43%)Patients with ESCC had an MPR rate of 42.11%; The SLD regression rate has a certain guiding relevance for the impact of immunotherapy, and the adoption of the NACI regimen may not raise the likelihood of problems in neoadjuvant treatment and surgery
CamrelizumabLiu et al[49], 202260Carboplatin + paclitaxel + camrelizumabProceeded to surgery, 51/60 (85.00%); R0 resection, 50/51 (98.00%); pCR, 5/20 (39.20%)Camrelizumab plus weekly chemotherapy as a promising neoadjuvant treatment for locally advanced ESCC, and further phase 3 randomized controlled trial is warranted
CamrelizumabLiu et al[50], 202256Cisplatin + paclitaxel + camrelizumabProceeded to surgery, 51/56 (77.40%); pCR, 18/56 (39.20%); MPR, 12/56 (21.43%)Camrelizumab plus neoadjuvant chemotherapy in resectable ESCC demonstrates promising efficacy with acceptable toxicity, providing a feasible and effective option
PembrolizumabLi et al[51], 202120Carboplatin + paclitaxel + pembrolizumab + radiotherapy Proceeded to surgery, 18/20 (90.00%); pCR, 10/18 (55.60%)PPCT was safe and did not delay surgery in resectable EC
PembrolizumabZhu et al[53], 202231Carboplatin + paclitaxel + pembrolizumab + radiotherapyProceeded to surgery, 28/29 (96.55%); pCR, 7/31 (22.58%)Incorporating anti–PD-1 therapy into neoadjuvant chemoradiation and adjuvant treatment of GEJ adenocarcinoma may improve pCR and survival
PembrolizumabHuang et al[54], 202154Nedaplatin + docetaxel + pembrolizumab = 23 vs. nedaplatin + docetaxel = 31pCR 30.4%/9.7%; ORR 86.9%/95.7%Pembrolizumab combined with chemotherapy showed promising activity with a manageable safety profile and it could offer a potential new neoadjuvant treatment approach for patients with ESCC
PembrolizumabDuan et al[55], 202218Nedaplatin + paclitaxel + pembrolizumab = 13 or nedaplatin + docetaxel +Proceeded to surgery, 13/18 (72.22%); MPR, 9/13 (69.20%); pCR, 6/13 (46.15%)The combination of neoadjuvant immunotherapy and chemotherapy for ESCC is associated with a high pathological response and immunologic effects in the tumor microenvironment
pembrolizumab = 5
TislelizumabYan et al[56], 202245Carboplatin + paclitaxel + tislelizumabProceeded to surgery, 36/45 (80.00%); MPR (69.20%); pCR (50.00%)Tislelizumab plus chemotherapy as neoadjuvant therapy demonstrates promising antitumor activity for resectable ESCC with high rates of MPR, pCR, and R0 resection, as well as acceptable tolerability
SintilimabChen et al[57], 202330Cisplatin + S1 + paclitaxel + sintilimabProceeded to surgery, 30/30 (100.00%); MPR (50.00%); pCR (20.00%)Neoadjuvant sintilimab plus platinum-based triplet chemotherapy appeared safe and feasible, did not delay surgery and induced a pCR rate of 20.0% in patients with potentially resectable ESCC
Atezolizumabvan den Ende et al[58], 202140Carboplatin + Paclitaxel + Atezolizumab + RadiotherapyProceeded to surgery, 33/40 (82.50%); MPR (50.00%); pCR, 10/40 (25.00%)The addition of atezolizumab to conventional nCRT for resectable EC was feasible without compromising surgical outcomes
ToripalimabXing et al[59], 202130Cisplatin + paclitaxel + toripalimab D3 vs. cisplatin + paclitaxel + toripalimab D1Proceeded to surgery, 11/15 vs. 13/15; pCR 4/15 vs. 1/15The study showed that delaying toripalimab to day 3 in chemoimmunotherapy might achieve a higher pCR rate than that on the same day
ToripalimabHe et al[60], 202220Carboplatin + paclitaxel + toripalimabProceeded to surgery, 16/20; R0 resection, 14/16; MPR, 7/16; pCR, 4/16The combination of toripalimab plus paclitaxel and carboplatin is safe, feasible, and effective in locally advanced resectable ESCC
ToripalimabGao et al[61], 202220Cisplatin + docetaxel + toripalimabORR, 14/20; MPR, 5/12; pCR, 2/12 Toripalimab combined with docetaxel and cisplatin as a novel neoadjuvant therapy was safe and effective in locally advanced ESCC
ToripalimabZhang et al[62], 202360S1 + paclitaxel + toripalimabR0 resection, 55/60; MPR, 27/60; pCR, 16/60Neoadjuvant therapy with toripalimab, nab-paclitaxel and S1 was less toxic and showed promising antitumor activity in patients with resectable ESCC
NivolumabKelly et al[63], 2021794Chemoradiotherapy+ nivolumab = 532 vs. chemoradiotherapy+ placebo = 262DFS, 22.4/11.0 mo; distant recurrence, 29/39%; locoregional recurrence, 12/17%Nivolumab adjuvant treatment significantly increased DFS compared to placebo in patients with resected esophagus or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy